Signal #104552 · SEC 8-K

$BMRN SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $BMRN filing catalyst

Why did $BMRN trigger an AI stock catalyst alert?

$BMRN triggered a Stock Catalyst AI alert on 2026-11-02 00:00:00 UTC for a SEC 8-K filing (AI Score: -6.5/10). Headline: BioMarin Slashes FY Guidance: Non-GAAP EPS Cut by ~40% Despite Q3 Revenue Growth. Key points: - Q3 2026 revenue grew 32% YoY to $1.025B, driven by metabolic condition therapies (+44%). - GAAP net loss widened to -$123M (-$0.63/sh) vs -$31M (-$0.16/sh) YoY; Non-GAAP EPS came in at $0.23. - Full-year 2026 Non-GAAP diluted EPS guidance slashed to $2.80–$3.10 (previously $4.90–$5.10); revenue outlook reduced.

How did $BMRN stock react after the SEC filing?

After the SEC 8-K for $BMRN, observed market reaction: T0 price $57.44. Past moves do not guarantee future results.

Where can I get real-time $BMRN SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $BMRN via Telegram and the VIP Web Terminal from €10/month.

$BMRN

$BMRN – BioMarin Slashes FY Guidance: Non-GAAP EPS Cut by ~40% Despite Q3 Revenue Growth

BIOMARIN PHARMACEUTICAL INC

2026-11-02 00:00:00 UTC · SEC 8-K · All $BMRN

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-6.5 / 10)

Q3 2026 revenue grew 32% YoY to $1.025B, driven by metabolic condition therapies (+44%).
GAAP net loss widened to -$123M (-$0.63/sh) vs -$31M (-$0.16/sh) YoY; Non-GAAP EPS came in at $0.23.
Full-year 2026 Non-GAAP diluted EPS guidance slashed to $2.80–$3.10 (previously $4.90–$5.10); revenue outlook reduced.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →